Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor.
This retrospective study evaluated 73 patients with newly diagnosed FLT3-mutated AML treated with frontline triplet regi...